Denali therapeutics inc. (DNLI)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16
Collaboration revenue:
Collaboration revenue from customers

26,678

129,160

0

0

Operating expenses:
Research and development

193,382

143,183

74,460

75,702

General and administrative

46,480

32,349

15,680

11,731

Total operating expenses

239,862

175,532

90,140

87,433

Loss from operations

-213,184

-46,372

-90,140

-87,433

Interest and other income, net

15,219

10,132

1,955

781

Loss before income taxes

-197,965

-36,240

-88,185

-

Income tax benefit

-400

0

0

-

Net loss

-197,614

-36,240

-88,185

-86,652

Other comprehensive income (loss):
Net unrealized gain on marketable securities, net of tax

999

-281

5

-373

Comprehensive loss

-196,615

-36,521

-88,180

-87,025

Net loss per share, basic and diluted (usd per share)

-2.07

-0.39

-5.89

-13.49

Weighted average number of shares outstanding, basic and diluted (in shares)

95,608

92,621

14,964

6,424